🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It is unacceptable that an important product to treat people with bleeding disorders (Octim intranasal desmopressin spray) can become unavailable for so many years with no alternative. We should judge companies by how good their back-up supply plans are. #eahad2025

Terrific and provocative data from Moik et al/Cihan Ay Vienna CATS group showing how starting ICI tx can lead to CRP rise/drop. CRP rise strongly associated with cancer-VTE. Important implications for understanding the pro-inflammatory state induced by ICI therapy

While we are approaching a century of first description of von Willebrand disease, there are still so many open questions. Omid Seidizadeh calls on the importance to better understand the most common inherited disease. #EHAD2025 EAHAD

It was a very enlightening lecture. Omid Seidizadeh presented estimates of expected prevalence of von Willebrand disease. He also revealed the year of his birth 😉

Read this State Of The Art review on risk assessment and prevention of cancer-associated VTE in ambulatory patients with solid malignancies! Nikola Vladić Cihan Ay Ingrid Pabinger Full paper here: rpthjournal.org/article/S2475-…

One most important sessions of #EAHAD2025, on #aging in #bleedingdisorders #hemophilia, chaired by F Baghaei & PM Mannucci, with #frailty covered by William McKeown, #thrombosis by Cihan Ay , and #psychosocial by Christina Burgess. Great choice of #EAHADCongress President

#EAHAD2025 discussed the management of thrombosis in Hemophilia patients by presentation of ⁦Cihan Ay⁩

📖 This weekend don't miss our KIReports #ISNFridaySelection: A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients with End-Stage Kidney Disease on Hemodialysis kireports.org/article/S2468-…

Join us for the next edition of our National Thrombosis Seminar series: "Biomarkers of #Hemostasis in #Cancer - Association with #Thrombosis, Therapy Response, and Disease Prognosis." Featuring: Cihan Ay Date: March 18 - 1-2 PM ET. Register: buff.ly/41wfKAV.

The CAT-BLED study of 779 cancer patients shows that high GDF-15 levels are linked to major bleeding risks during systemic therapies. It highlights its potential as a key biomarker for bleeding risk prediction & prevention jacc.org/doi/abs/10.101… #JACCCardioOnc #VTE Cihan Ay

Exited to share our paper on biological aging in #hemophilia, an inherited bleeding disorder with significant improvements in life expectancy over the last decades. Our results indicate an accelerated biological aging in people with hemophilia. ➡️ doi.org/10.3324/haemat…

How does #haemophilia affect the biological #ageingprocess❓🩸 Researchers from #MedUniVienna have now shown that people with this congenital #bleedingdisorder have a significantly increased #biologicalage. ➡️ bit.ly/4kZxfBt Haematologica Cihan Ay

📢JTH is proud to announce the recipients of the 2025 JTH Editors’ Awards! These prestigious awards honor 6 early career investigators for their top articles in thrombosis & hemostasis. Join us in congratulating the winners🎉 & learn more: bit.ly/4lc2pFR

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

Presented at #ACC25: In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results:

Mahé Isabelle NEJM INNOVTE INVENT-VTE Laurent Bertoletti Francis Couturaud manuel monreal Ander Cohen ISTH Peter Verhamme Philippe Girard Elegant editorial on the importance of capturing and reporting bleeding events in trials assessing anticoagulation in patients with cancer by Prof. Simon Noble in NEJM nejm.org/doi/full/10.10…

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

Big congrats to Stephan Nopp on his successful PhD defense! 🎓👏 It was a real pleasure working with you – smart, dedicated, and a true team player. Wishing you all the best for what’s next!